Skip to main content
. 2022 Oct 5;17(10):e0272372. doi: 10.1371/journal.pone.0272372

Table 2. Concomitant in-hospital treatment.

Concomitant in-hospital treatment: N Percentage
SABA/SAMA aerosol via nebulizer 165 95.4%
Oral corticosteroids 163 94.2%
Antibiotics 133 76.9%
O2-suppletion 139 80.3%
NIV 35 20.2%

In-hospital treatment in addition to treatment with HFNC for all included patients. Values shown are the number of patients (N) and percentage (%). SABA: short-acting β-agonist; SAMA: short-acting muscarinic antagonist; NIV: Non-invasive ventilation.